Targets › IL3RA
8 programs from 8 companies in 22 trials: 17 Phase 1, 5 Phase 2; Oncology; next expected readout Dec 2026.
Cell surface receptor for IL3 expressed on hematopoietic progenitor cells, monocytes and B-lymphocytes that controls the production and differentiation of hematopoietic progenitor cells into lineage-restricted cells. Ligand stimulation rapidly induces hetrodimerization with IL3RB, phosphorylation and enzyme activity of effector proteins such as JAK2 and PI3K that play a role in signaling cell proliferation and…. (UniProt, P26951)
Open in Phaseline: the race on IL3RA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AbbVie | Pivekimab Sunirine Interleukin-3 receptor subunit alpha binding agent | IL3RA | Phase 2 | Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm | Dec 2026 |
| Stemline Therapeutics | Tagraxofusp Interleukin-3 receptor subunit alpha binding agent; Elongation factor 2 inhibitor | IL3RA, EEF2 | Phase 2 | Acute Myeloid Leukemia; Blastic Plasmacytoid Dendritic Cell Neoplasm; Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN); Myelofibrosis … | Feb 2028 |
| Children's Oncology Group | Flotetuzumab Interleukin-3 receptor subunit alpha binding agent; T cell surface glycoprotein CD3 binding agent | IL3RA, CD3E, CD3G, CD3D | Phase 1 | Recurrent Acute Myeloid Leukemia | Mar 2027 |
| Aptevo Therapeutics | APVO436 CD123-targeting bispecific T-cell engager (BiTE) | IL3RA | Phase 1 | Acute Myeloid Leukemia (AML) | Oct 2027 |
| Fondazione Matilde Tettamanti Menotti De Marchi Onlus | CARCIK CD123/33 CAR-T cell therapy targeting CD123 and CD33 | IL3RA, ITGAM | Phase 1 | AML (Acute Myeloid Leukemia) | Oct 2028 |
| Orum Therapeutics USA | ORM-1153 anti-CD123 antibody-drug conjugate | IL3RA | Phase 1 | CD123+ Acute Myeloid Leukemia | Dec 2028 |
| Stephan Grupp MD PhD | CART123 cells anti-CD123 chimeric antigen receptor T cells with TCRζ/4-1BB costimulatory domains | IL3RA | Phase 1 | Acute Myeloid Leukemia (AML) | May 2029 |
| St. Jude Children's Research Hospital | CD123-CAR T CAR-T cell therapy targeting CD123 (IL3RA) antigen on leukemic and MDS cells | IL3RA | Phase 1 | AML/MDS | Jul 2029 |
Acute Myeloid Leukemia (8) Blastic Plasmacytoid Dendritic Cell Neoplasm (2) Acute Myeloid Leukemia (AML) (2) CD123+ Acute Myeloid Leukemia (1) AML/MDS (1) AML (Acute Myeloid Leukemia) (1) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (1) Myelofibrosis (1) Chronic Myelomonocytic Leukemia (1) Refractory Acute Myeloid Leukemia (1) Hematologic Malignancy (1) Acute Myeloid Leukaemia (AML) (1)
mixed (4), small molecule (4)
AbbVie (1) Orum Therapeutics USA (1) St. Jude Children's Research Hospital (1) Fondazione Matilde Tettamanti Menotti De Marchi Onlus (1) Aptevo Therapeutics (1) Stemline Therapeutics (1) Stephan Grupp MD PhD (1) Children's Oncology Group (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.